摘要
新型冠状病毒(2019 novel coronavirus,2019-nCoV)与急性呼吸综合征冠状病毒(severe acute respiratory syndromes coronavirus,SARS-Co V)的核酸和编码的病毒蛋白高度同源,预示其生物学功能也可能非常相似。2019-nCoV利用其刺突蛋白(spike protein,S)的S1亚基与宿主细胞表面的血管紧张素转换酶2(angiotensin converting enzyme 2,ACE2)受体结合,同时利用宿主蛋白酶切割S蛋白促进发生膜融合,进而内吞入胞。阻断2019-nCoV入胞过程的抑制剂主要可分为中和抗体/受体抑制剂、蛋白酶抑制剂和内吞调节因子抑制剂。目前,对2019-nCoV的认识仍然非常有限。相信随着研究的不断推进,能够更加深刻地认识病毒的致病机制,开发出更高效的抗病毒药物。
The pathogen was identified as a new type of coronavirus and named as 2019-nCoV.The nucleic acids and encoded viral proteins of 2019-nCoV and SARS-Co V are highly homologous,indicating that their biological functions may also be very similar.2019-nCoV uses the S1 subunit of its spike protein binding to the ACE2 receptor on the surface of the host cell,and uses the host protease to cleave the S protein to promote membrane fusion and then endocytosis.Inhibitors that blocking 2019-nCoV invasion can be divided into neutralizing antibody/receptor inhibitors,protease inhibitors,and endocytosis regulator inhibitors.At present,the understanding of 2019-nCoV is still very limited.It is believed that with the continuous advancement of research,we can better understand the pathogenic mechanism of the virus and develop more efficient antiviral drugs.
作者
师悦嫄
汪德强
Shi Yueyuan;Wang Deqiang(Key Laboratory of Clinical Laboratory Diagnosis,Chongqing Medical University;Key Laboratory of Molecular Biology on Infectious Diseases Established by Ministry of Education,Chongqing Medical University)
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2020年第7期845-848,共4页
Journal of Chongqing Medical University
基金
新型冠状病毒抗原抗体设计制备与临床应用资助项目(编号:cstc2020jscx-fyzx0050)。
关键词
新型冠状病毒
入胞机制
入胞抑制剂
2019 novel coronavirus
invasion mechanism
entry inhibitors
